24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Mori Arkin
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
17:56
Mobileye first quarter revenue falls by almost 50% as clients cut back on spending to clear excess stock
14:00
Melio names Boaz BenDavid as its first Chief Financial Officer
13:28
Check Point registers higher than expected Q1 profit helped by growth of AI-powered security platform
09:26
Microsoft explains how Generative AI impacts IP law and compliance
More stories
Buzz
Most popular
Daily
Weekly
1
Nvidia announces $700 million acquisition of Run:ai
2
Nvidia on verge of completing $700 million acquisition of Run:ai
3
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
4
Nvidia continues Israel shopping spree with acquisition of Deci
5
Nagomi Security raises $23 million Series A for proactive defense platform
More news
Mori Arkin
5 stories about Mori Arkin
Exalenz Bioscience Acquired for $49M
19.02.20
|
Golan Hazani
Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!
Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company
19.02.20
|
Golan Hazani
Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source
Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel
20.02.18
|
Meir Orbach
The incubator program has a five year budget of 20 million euros
Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO
31.08.17
|
Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
Anti-Acne Drug Developer Plans Nasdaq IPO
15.08.17
|
Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year
Please ensure Javascript is enabled for purposes of
website accessibility